Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.51 - $4.66 $23,870 - $44,316
-9,510 Reduced 46.67%
10,867 $43,000
Q1 2024

May 15, 2024

BUY
$2.68 - $3.63 $54,610 - $73,968
20,377 New
20,377 $69,000

Others Institutions Holding VIGL

About Vigil Neuroscience, Inc.


  • Ticker VIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,268,600
  • Market Cap $48.1M
  • Description
  • Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...
More about VIGL
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.